Loading...

Reiter Robert

Title(s)Professor, Urology
Phone(310) 794-7224
vCardDownload vCard
    Other Positions
    Title(s)Director, JCCC Genitourinary Oncology Program Area

    Title(s)Physician, Bladder Cancer Program

    Title(s)Physician, Kidney Cancer Program

    Title(s)Physician, Testicular Cancer Program


    Collapse Research 
    Collapse Research Activities and Funding
    Multifunctional immunoPET tracers for pancreatic and prostate cancer
    NIH/NCI R01CA174294Apr 1, 2013 - Jul 31, 2021
    Role: Co-Principal Investigator
    UCLA SPORE in Prostate Cancer
    NIH/NCI P50CA092131Jul 1, 2001 - Aug 31, 2019
    Role: Principal Investigator
    MARKERS OF ANDROGEN INDEPENDENT PROSTATE CANCER
    NIH/NCI K08CA074169Jul 29, 1997 - Jun 30, 2002
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Osadchiy V, Eleswarapu SV, Mills SA, Pollard ME, Reiter RE, Mills JN. Efficacy of a preprostatectomy multi-modal penile rehabilitation regimen on recovery of postoperative erectile function. Int J Impot Res. 2019 Sep 02. PMID: 31474755.
      View in: PubMed
    2. Calais J, Ceci F, Eiber M, Hope TA, Hofman MS, Rischpler C, Bach-Gansmo T, Nanni C, Savir-Baruch B, Elashoff D, Grogan T, Dahlbom M, Slavik R, Gartmann J, Nguyen K, Lok V, Jadvar H, Kishan AU, Rettig MB, Reiter RE, Fendler WP, Czernin J. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019 Jul 30. PMID: 31375469.
      View in: PubMed
    3. Bajgiran AM, Mirak SA, Sung K, Sisk AE, Reiter RE, Raman SS. Apparent Diffusion Coefficient (ADC) Ratio Versus Conventional ADC for Detecting Clinically Significant Prostate Cancer With 3-T MRI. AJR Am J Roentgenol. 2019 Jun 19; 1-9. PMID: 31216201.
      View in: PubMed
    4. Zettlitz KA, Tsai WK, Knowles SM, Salazar FB, Kobayashi N, Reiter RE, Wu AM. [89Zr]A2cDb Immuno-PET of Prostate Cancer in a Human Prostate Stem Cell Antigen Knock-in (hPSCA KI) Syngeneic Model. Mol Imaging Biol. 2019 Jun 17. PMID: 31209779.
      View in: PubMed
    5. Johnson DC, Reiter RE. Focal Therapy Should Not Be Considered for Men with Gleason Grade Group 3-5 Prostate Cancer. Eur Urol Focus. 2019 Jun 12. PMID: 31202786.
      View in: PubMed
    6. Dorff TB, Fanti S, Farolfi A, Reiter RE, Sadun TY, Sartor O. The Evolving Role of Prostate-Specific Membrane Antigen-Based Diagnostics and Therapeutics in Prostate Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:321-330. PMID: 31099673.
      View in: PubMed
    7. Johnson DC, Yang JJ, Kwan L, Barsa DE, Mirak SA, Pooli A, Sadun T, Jayadevan R, Zhou S, Priester AM, Natarajan S, Bajgiran AM, Shakeri S, Sisk A, Felker ER, Raman SS, Marks LS, Reiter RE. Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection. Cancer. 2019 May 01. PMID: 31042322.
      View in: PubMed
    8. Lubin DJ, Holden SB, Rettig MB, Reiter RE, King CR, Lee JM, Wallace DW, Calais J. Prostate Cancer Pulmonary Metastasis Presenting as a Ground-Glass Pulmonary Nodule on 68Ga-PSMA-11 PET/CT. Clin Nucl Med. 2019 May; 44(5):e353-e356. PMID: 30789399.
      View in: PubMed
    9. Wibulpolprasert P, Raman SS, Hsu W, Margolis DJA, Asvadi NH, Khoshnoodi P, Moshksar A, Tan N, Ahuja P, Maehara CK, Huang J, Sayre J, Lu DSK, Reiter RE. Detection and Localization of Prostate Cancer at 3-T Multiparametric MRI Using PI-RADS Segmentation. AJR Am J Roentgenol. 2019 Apr 17; W1-W10. PMID: 30995090.
      View in: PubMed
    10. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. Eur Urol. 2019 Apr 13. PMID: 30992160.
      View in: PubMed
    11. Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. BMC Cancer. 2019 Apr 01; 19(1):291. PMID: 30935383.
      View in: PubMed
    12. Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY. A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol. 2019 Apr; 201(4):682-692. PMID: 30077557.
      View in: PubMed
    13. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Mar 28. PMID: 30920593.
      View in: PubMed
    14. Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 Mar 27. PMID: 30928160.
      View in: PubMed
    15. Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Mol Cancer Res. 2019 Jun; 17(6):1235-1240. PMID: 30918106.
      View in: PubMed
    16. Mirak SA, Shakeri S, Bajgiran AM, Felker ER, Sung KH, Asvadi NH, Khoshnoodi P, Markovic D, Ponzini D, Ahuja P, Sisk A, Reiter RE, Lu D, Raman SS. Three Tesla Multiparametric Magnetic Resonance Imaging: Comparison of Performance with and without Endorectal Coil for Prostate Cancer Detection, PI-RADS™ version 2 Category and Staging with Whole Mount Histopathology Correlation. J Urol. 2019 03; 201(3):496-502. PMID: 30273608.
      View in: PubMed
    17. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 Feb 25. PMID: 30804427.
      View in: PubMed
    18. Wang C, Raldow AC, Nickols NG, Nguyen PL, Spratt DE, Dess RT, Yu JB, King CR, Chu FI, Chamie K, Litwin MS, Saigal CS, Reiter RE, Liu ST, Rettig MB, Chang AJ, Steinberg ML, Kupelian PA, Kishan AU. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. Eur Urol Oncol. 2019 Feb 01. PMID: 31411981.
      View in: PubMed
    19. Simopoulos DN, Sisk AE, Priester A, Felker ER, Kwan L, Delfin MK, Reiter RE, Marks LS. Cancer core length from targeted biopsy: an index of prostate cancer volume and pathological stage. BJU Int. 2019 Jan 29. PMID: 30694605.
      View in: PubMed
    20. Houlahan KE, Salmasi A, Sadun TY, Pooli A, Felker ER, Livingstone J, Huang V, Raman SS, Ahuja P, Sisk AE, Boutros PC, Reiter RE. Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer. Eur Urol. 2019 Jan 24. PMID: 30685078.
      View in: PubMed
    21. Kishan AU, Wang X, Seiferheld W, Collette L, Sandler KA, Sandler HM, Bolla M, Maingon P, De Reijke T, Hanks GE, Nickols NG, Rettig M, Drakaki A, Reiter RE, Spratt DE, Kupelian PA, Steinberg ML, King CR. Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis. JAMA Oncol. 2019 Jan 01; 5(1):91-96. PMID: 30326032.
      View in: PubMed
    22. Faiena I, Salmasi A, Mendhiratta N, Markovic D, Ahuja P, Hsu W, Elashoff DA, Raman SS, Reiter RE. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy. J Urol. 2019 01; 201(1):91-97. PMID: 30577397.
      View in: PubMed
    23. Faiena I, Salmasi A, Mendhiratta N, Markovic D, Ahuja P, Hsu W, Elashoff DA, Raman SS, Reiter RE. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy. J Urol. 2019 01; 201(1):91-97. PMID: 30142318.
      View in: PubMed
    24. Sadun TY, Reiter RE. Adjusting Our Approach to Multiparametric Magnetic Resonance Imaging-based Targeted Prostate Biopsies: Considerations After the FUTURE Trial. Eur Urol. 2019 04; 75(4):591-592. PMID: 30591355.
      View in: PubMed
    25. Johnson DC, Raman SS, Mirak SA, Kwan L, Bajgiran AM, Hsu W, Maehara CK, Ahuja P, Faiena I, Pooli A, Salmasi A, Sisk A, Felker ER, Lu DSK, Reiter RE. Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. Eur Urol. 2019 May; 75(5):712-720. PMID: 30509763.
      View in: PubMed
    26. Tsai WK, Zettlitz KA, Tavaré R, Kobayashi N, Reiter RE, Wu AM. Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody. Theranostics. 2018; 8(21):5903-5914. PMID: 30613270.
      View in: PubMed
    27. Asvadi NH, Afshari Mirak S, Mohammadian Bajgiran A, Khoshnoodi P, Wibulpolprasert P, Margolis D, Sisk A, Reiter RE, Raman SS. 3T multiparametric MR imaging, PIRADSv2-based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard. Abdom Radiol (NY). 2018 Nov; 43(11):3117-3124. PMID: 29725743.
      View in: PubMed
    28. Lückerath K, Wei L, Fendler WP, Evans-Axelsson S, Stuparu AD, Slavik R, Mona CE, Calais J, Rettig M, Reiter RE, Herrmann K, Radu CG, Czernin J, Eiber M. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res. 2018 Oct 29; 8(1):96. PMID: 30374743.
      View in: PubMed
    29. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 Oct 18; 175(3):889. PMID: 30340047.
      View in: PubMed
    30. Zhang M, Kobayashi N, Zettlitz KA, Kono EA, Yamashiro JM, Tsai WK, Jiang ZK, Tran CP, Wang C, Guan J, Wu AM, Reiter RE. Near-Infrared Dye-Labeled Anti-Prostate Stem Cell Antigen Minibody Enables Real-Time Fluorescence Imaging and Targeted Surgery in Translational Mouse Models. Clin Cancer Res. 2019 Jan 01; 25(1):188-200. PMID: 30301826.
      View in: PubMed
    31. Polverari G, Ceci F, Allen-Auerbach M, Gupta P, Fishbein MC, Reiter RE, Lee JM, Hope TA, Carroll RM, Czernin J, Calais J. Solitary Mucinous Prostate Adenocarcinoma Lung Metastasis Detected by 68Ga-PSMA-11 PET/CT. Clin Genitourin Cancer. 2019 Feb; 17(1):e53-e55. PMID: 30293922.
      View in: PubMed
    32. Nagarajan MB, Raman SS, Lo P, Lin WC, Khoshnoodi P, Sayre JW, Ramakrishna B, Ahuja P, Huang J, Margolis DJA, Lu DSK, Reiter RE, Goldin JG, Brown MS, Enzmann DR. Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. Abdom Radiol (NY). 2018 Sep; 43(9):2487-2496. PMID: 29460041.
      View in: PubMed
    33. Kang JJ, Reiter RE, Steinberg ML, King CR. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. Eur Urol Oncol. 2018 Oct; 1(5):378-385. PMID: 31158076.
      View in: PubMed
    34. Wu HH, Priester A, Khoshnoodi P, Zhang Z, Shakeri S, Afshari Mirak S, Asvadi NH, Ahuja P, Sung K, Natarajan S, Sisk A, Reiter R, Raman S, Enzmann D. A system using patient-specific 3D-printed molds to spatially align in vivo MRI with ex vivo MRI and whole-mount histopathology for prostate cancer research. J Magn Reson Imaging. 2019 Jan; 49(1):270-279. PMID: 30069968.
      View in: PubMed
    35. Salmasi A, Faiena I, Wu J, Sisk AE, Sachveda A, Vandel JJ, Chamie K, Marks LS, Reiter RE. Radical prostatectomy then and now: Surgical overtreatment of prostate cancer is declining from 2009 to 2016 at a tertiary referral center. Urol Oncol. 2018 09; 36(9):401.e19-401.e25. PMID: 30064933.
      View in: PubMed
    36. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 Jul 26; 174(3):758-769.e9. PMID: 30033370.
      View in: PubMed
    37. Priester A, Wu H, Khoshnoodi P, Schneider D, Zhang Z, Asvadi NH, Sisk A, Raman S, Reiter R, Grundfest W, Marks LS, Natarajan S. Registration Accuracy of Patient-Specific, Three-Dimensional-Printed Prostate Molds for Correlating Pathology With Magnetic Resonance Imaging. IEEE Trans Biomed Eng. 2019 Jan; 66(1):14-22. PMID: 29993431.
      View in: PubMed
    38. Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG. Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. J Nucl Med. 2018 Nov; 59(11):1714-1721. PMID: 29653978.
      View in: PubMed
    39. Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. Int J Radiat Oncol Biol Phys. 2018 Jul 15; 101(4):883-888. PMID: 29976500.
      View in: PubMed
    40. Zettlitz KA, Tsai WK, Knowles SM, Kobayashi N, Donahue TR, Reiter RE, Wu AM. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody. J Nucl Med. 2018 Sep; 59(9):1398-1405. PMID: 29602820.
      View in: PubMed
    41. Lückerath K, Stuparu AD, Wei L, Kim W, Radu CG, Mona CE, Calais J, Rettig M, Reiter RE, Czernin J, Slavik R, Herrmann K, Eiber M, Fendler WP. Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. J Nucl Med. 2018 Sep; 59(9):1392-1397. PMID: 29602819.
      View in: PubMed
    42. Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk AE, Grogan T, McCullough D, Bennett J, Bailey H, Lawrence HJ, Elashoff DA, Marks LS, Raman SS, Febbo PG, Reiter RE. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy. J Urol. 2018 09; 200(3):564-572. PMID: 29524506.
      View in: PubMed
    43. Kishan AU, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Sandler KA, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Stephenson AJ, Klein EA, Song DY, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco S, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA. 2018 03 06; 319(9):896-905. PMID: 29509865.
      View in: PubMed
    44. Miller ET, Salmasi A, Reiter RE. Anatomic and Molecular Imaging in Prostate Cancer. Cold Spring Harb Perspect Med. 2018 03 01; 8(3). PMID: 28710256.
      View in: PubMed
    45. Kang JJ, Reiter RE, Kummer N, DeKernion J, Steinberg ML, King CR. Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy. Am J Clin Oncol. 2018 Jan; 41(1):1-5. PMID: 26237192.
      View in: PubMed
    46. Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med. 2018 03; 59(3):434-441. PMID: 29242398.
      View in: PubMed
    47. Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst. 2017 Dec 01; 109(12). PMID: 29206995.
      View in: PubMed
    48. Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, Hope T, Reiter R, Maurer T, Weber WA, Fendler WP. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2018 03; 59(3):469-478. PMID: 29123012.
      View in: PubMed
    49. Tan N, Shen L, Khoshnoodi P, Alcalá HE, Yu W, Hsu W, Reiter RE, Lu DY, Raman SS. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology. J Urol. 2018 May; 199(5):1218-1223. PMID: 29128577.
      View in: PubMed
    50. Kishan AU, Cheng EM, Schmidt E, Saigal C, Reiter RE, Kupelian PA, Steinberg ML, King CR. Use of the Electronic Medical Record to Facilitate Intervention for Patients With Rising Prostate-Specific Antigen Values After Radical Prostatectomy: A Feasibility Study. JCO Clin Cancer Inform. 2017 11; 1:1-6. PMID: 30657383.
      View in: PubMed
    51. Priceman SJ, Gerdts EA, Tilakawardane D, Kennewick KT, Murad JP, Park AK, Jeang B, Yamaguchi Y, Yang X, Urak R, Weng L, Chang WC, Wright S, Pal S, Reiter RE, Wu AM, Brown CE, Forman SJ. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. Oncoimmunology. 2018; 7(2):e1380764. PMID: 29308300.
      View in: PubMed
    52. Donin NM, Reiter RE. Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. J Nucl Med. 2018 02; 59(2):177-182. PMID: 28986509.
      View in: PubMed
    53. Nassiri N, Chang E, Lieu P, Priester AM, Margolis DJA, Huang J, Reiter RE, Dorey FJ, Marks LS, Natarajan S. Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy. J Urol. 2018 02; 199(2):453-458. PMID: 28830754.
      View in: PubMed
    54. Johnson DC, Reiter RE. Multi-parametric magnetic resonance imaging as a management decision tool. Transl Androl Urol. 2017 Jun; 6(3):472-482. PMID: 28725589.
      View in: PubMed
    55. Hegde JV, Veruttipong D, Said JW, Reiter RE, Steinberg ML, King CR, Kishan AU. Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer. Urology. 2017 Sep; 107:171-177. PMID: 28552819.
      View in: PubMed
    56. Jamshidi N, Margolis DJ, Raman S, Huang J, Reiter RE, Kuo MD. Multiregional Radiogenomic Assessment of Prostate Microenvironments with Multiparametric MR Imaging and DNA Whole-Exome Sequencing of Prostate Glands with Adenocarcinoma. Radiology. 2017 07; 284(1):109-119. PMID: 28453432.
      View in: PubMed
    57. Ellis-Caleo T, Hegde JV, Batth S, Mesko S, Reiter R, Margolis D, Kamrava M. Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer. Anticancer Res. 2017 03; 37(3):1237-1242. PMID: 28314287.
      View in: PubMed
    58. Stoyanova T, Riedinger M, Lin S, Faltermeier CM, Smith BA, Zhang KX, Going CC, Goldstein AS, Lee JK, Drake JM, Rice MA, Hsu EC, Nowroozizadeh B, Castor B, Orellana SY, Blum SM, Cheng D, Pienta KJ, Reiter RE, Pitteri SJ, Huang J, Witte ON. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2016 10 18; 113(42):E6457-E6466. PMID: 27694579.
      View in: PubMed
    59. Reiter RE. Risk stratification of prostate cancer 2016. Scand J Clin Lab Invest Suppl. 2016; 245:S54-9. PMID: 27533326.
      View in: PubMed
    60. Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M, Keppler JS, Reiter RE, Wu AM, Weber WA, Scher HI, Larson SM, Morris MJ. First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. J Nucl Med. 2016 Dec; 57(12):1858-1864. PMID: 27516450.
      View in: PubMed
    61. Priester A, Natarajan S, Khoshnoodi P, Margolis DJ, Raman SS, Reiter RE, Huang J, Grundfest W, Marks LS. Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. J Urol. 2017 02; 197(2):320-326. PMID: 27484386.
      View in: PubMed
    62. Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. Eur Urol. 2017 05; 71(5):766-773. PMID: 27452951.
      View in: PubMed
    63. Taneja SS, Bennett J, Coleman J, Grubb R, Andriole G, Reiter RE, Marks L, Azzouzi AR, Emberton M. Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States. J Urol. 2016 Oct; 196(4):1096-104. PMID: 27291652.
      View in: PubMed
    64. Prado K, Reiter RE. Is Targeted Biopsy Applicable to Patients on Active Surveillance? Eur Urol. 2017 02; 71(2):181-182. PMID: 27292867.
      View in: PubMed
    65. Filson CP, Natarajan S, Margolis DJ, Huang J, Lieu P, Dorey FJ, Reiter RE, Marks LS. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer. 2016 Mar 15; 122(6):884-92. PMID: 26749141.
      View in: PubMed
    66. Sonn GA, Behesnilian AS, Jiang ZK, Zettlitz KA, Lepin EJ, Bentolila LA, Knowles SM, Lawrence D, Wu AM, Reiter RE. Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time. Clin Cancer Res. 2016 Mar 15; 22(6):1403-12. PMID: 26490315; PMCID: PMC4794340 [Available on 03/15/17].
    67. Nagarajan R, Iqbal Z, Burns B, Wilson NE, Sarma MK, Margolis DA, Reiter RE, Raman SS, Thomas MA. Accelerated echo planar J-resolved spectroscopic imaging in prostate cancer: a pilot validation of non-linear reconstruction using total variation and maximum entropy. NMR Biomed. 2015 Nov; 28(11):1366-73. PMID: 26346702.
      View in: PubMed
    68. Rakow-Penner RA, White NS, Margolis DJA, Parsons JK, Schenker-Ahmed N, Kuperman JM, Bartsch H, Choi HW, Bradley WG, Shabaik A, Huang J, Liss MA, Marks L, Kane CJ, Reiter RE, Raman SS, Karow DS, Dale AM. Prostate diffusion imaging with distortion correction. Magn Reson Imaging. 2015 Nov; 33(9):1178-1181. PMID: 26220859; PMCID: PMC4594204 [Available on 11/01/16].
    69. Tan N, Margolis DJ, Lu DY, King KG, Huang J, Reiter RE, Raman SS. Characteristics of Detected and Missed Prostate Cancer Foci on 3-T Multiparametric MRI Using an Endorectal Coil Correlated With Whole-Mount Thin-Section Histopathology. AJR Am J Roentgenol. 2015 Jul; 205(1):W87-92. PMID: 26102423; PMCID: PMC4898906.
    70. Li K, Zettlitz KA, Lipianskaya J, Zhou Y, Marks JD, Mallick P, Reiter RE, Wu AM. A fully human scFv phage display library for rapid antibody fragment reformatting. Protein Eng Des Sel. 2015 Oct; 28(10):307-16. PMID: 25991864.
      View in: PubMed
    71. Behesnilian AS, Reiter RE. Risk stratification of prostate cancer in the modern era. Curr Opin Urol. 2015 May; 25(3):246-51. PMID: 25730325.
      View in: PubMed
    72. Liss MA, White NS, Parsons JK, Schenker-Ahmed NM, Rakow-Penner R, Kuperman JM, Bartsch H, Choi HW, Mattrey RF, Bradley WG, Shabaik A, Huang J, Margolis DJ, Raman SS, Marks LS, Kane CJ, Reiter RE, Dale AM, Karow DS. MRI-Derived Restriction Spectrum Imaging Cellularity Index is Associated with High Grade Prostate Cancer on Radical Prostatectomy Specimens. Front Oncol. 2015; 5:30. PMID: 25741473; PMCID: PMC4330697.
    73. Kang JJ, Reiter RE, Steinberg ML, King CR. Ultrasensitive prostate specific antigen after prostatectomy reliably identifies patients requiring postoperative radiotherapy. J Urol. 2015 May; 193(5):1532-8. PMID: 25463990.
      View in: PubMed
    74. Knowles SM, Tavaré R, Zettlitz KA, Rochefort MM, Salazar FB, Jiang ZK, Reiter RE, Wu AM. Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer. Clin Cancer Res. 2014 Dec 15; 20(24):6367-78. PMID: 25326233.
      View in: PubMed
    75. Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, Marks LS, Huang J, Margolis DJ, Raman SS, Reiter RE. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol. 2015 Mar; 67(3):569-76. PMID: 25257029.
      View in: PubMed
    76. White NS, McDonald C, McDonald CR, Farid N, Kuperman J, Karow D, Schenker-Ahmed NM, Bartsch H, Rakow-Penner R, Holland D, Shabaik A, Bjørnerud A, Hope T, Hattangadi-Gluth J, Liss M, Parsons JK, Chen CC, Raman S, Margolis D, Reiter RE, Marks L, Kesari S, Mundt AJ, Kane CJ, Kaine CJ, Carter BS, Bradley WG, Dale AM. Diffusion-weighted imaging in cancer: physical foundations and applications of restriction spectrum imaging. Cancer Res. 2014 Sep 01; 74(17):4638-52. PMID: 25183788; PMCID: PMC4155409.
    77. Sonn GA, Filson CP, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ, Reiter RE, Marks LS. Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer. Urol Oncol. 2014 Oct; 32(7):952-7. PMID: 25027689; PMCID: PMC4254112.
    78. Le JD, Stephenson S, Brugger M, Lu DY, Lieu P, Sonn GA, Natarajan S, Dorey FJ, Huang J, Margolis DJ, Reiter RE, Marks LS. Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. J Urol. 2014 Nov; 192(5):1367-73. PMID: 24793118; PMCID: PMC4201866.
    79. Knowles SM, Zettlitz KA, Tavaré R, Rochefort MM, Salazar FB, Stout DB, Yazaki PJ, Reiter RE, Wu AM. Quantitative immunoPET of prostate cancer xenografts with 89Zr- and 124I-labeled anti-PSCA A11 minibody. J Nucl Med. 2014 Mar; 55(3):452-9. PMID: 24504052; PMCID: PMC4052832.
    80. Chamie K, Sonn GA, Finley DS, Tan N, Margolis DJ, Raman SS, Natarajan S, Huang J, Reiter RE. The role of magnetic resonance imaging in delineating clinically significant prostate cancer. Urology. 2014 Feb; 83(2):369-75. PMID: 24468511; PMCID: PMC3922632.
    81. Thomas MA, Nagarajan R, Huda A, Margolis D, Sarma MK, Sheng K, Reiter RE, Raman SS. Multidimensional MR spectroscopic imaging of prostate cancer in vivo. NMR Biomed. 2014 Jan; 27(1):53-66. PMID: 23904127.
      View in: PubMed
    82. Seiler D, Zheng J, Liu G, Wang S, Yamashiro J, Reiter RE, Huang J, Zeng G. Enrichment of putative prostate cancer stem cells after androgen deprivation: upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines. Prostate. 2013 Sep; 73(13):1378-90. PMID: 23728788.
      View in: PubMed
    83. Nagarajan R, Margolis DJ, Raman SS, Ouellette D, Sarma MK, Reiter RE, Thomas MA. MR Spectroscopic Imaging of Peripheral Zone in Prostate Cancer Using a 3T MRI Scanner: Endorectal versus External Phased Array Coils. Magn Reson Insights. 2013; 6:51-8. PMID: 25114544; PMCID: PMC4089813.
    84. Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ, Reiter RE, Marks LS. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol. 2014 Apr; 65(4):809-15. PMID: 23523537; PMCID: PMC3858524.
    85. Tan N, Margolis DJ, McClure TD, Thomas A, Finley DS, Reiter RE, Huang J, Raman SS. Radical prostatectomy: value of prostate MRI in surgical planning. Abdom Imaging. 2012 Aug; 37(4):664-74. PMID: 21993567.
      View in: PubMed
    86. Finley DS, Ellingson BM, Natarajan S, Zaw TM, Raman SS, Schulam P, Reiter RE, Margolis D. Diffusion tensor magnetic resonance tractography of the prostate: feasibility for mapping periprostatic fibers. Urology. 2012 Jul; 80(1):219-23. PMID: 22748877.
      View in: PubMed
    87. Nagarajan R, Margolis D, Raman S, Sarma MK, Sheng K, King CR, Verma G, Sayre J, Reiter RE, Thomas MA. MR spectroscopic imaging and diffusion-weighted imaging of prostate cancer with Gleason scores. J Magn Reson Imaging. 2012 Sep; 36(3):697-703. PMID: 22581787.
      View in: PubMed
    88. McClure TD, Margolis DJ, Reiter RE, Sayre JW, Thomas MA, Nagarajan R, Gulati M, Raman SS. Use of MR imaging to determine preservation of the neurovascular bundles at robotic-assisted laparoscopic prostatectomy. Radiology. 2012 Mar; 262(3):874-83. PMID: 22274837.
      View in: PubMed
    89. Nagarajan R, Margolis D, Raman S, Sheng K, King C, Reiter R, Thomas MA. Correlation of Gleason scores with diffusion-weighted imaging findings of prostate cancer. Adv Urol. 2012; 2012:374805. PMID: 22216026; PMCID: PMC3246296.
    90. Finley DS, Margolis D, Raman SS, Ellingson BM, Natarajan S, Tan N, Huang J, Reiter RE. Fine-tuning robot-assisted radical prostatectomy planning with MRI. Urol Oncol. 2013 Aug; 31(6):766-75. PMID: 21906964.
      View in: PubMed
    91. Goldstein AS, Drake JM, Burnes DL, Finley DS, Zhang H, Reiter RE, Huang J, Witte ON. Purification and direct transformation of epithelial progenitor cells from primary human prostate. Nat Protoc. 2011 May; 6(5):656-67. PMID: 21527922; PMCID: PMC3092477.
    92. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med. 2010 Dec; 16(12):1414-20. PMID: 21057494.
      View in: PubMed
    93. Lepin EJ, Leyton JV, Zhou Y, Olafsen T, Salazar FB, McCabe KE, Hahm S, Marks JD, Reiter RE, Wu AM. An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors. Eur J Nucl Med Mol Imaging. 2010 Aug; 37(8):1529-38. PMID: 20354850; PMCID: PMC2903645.
    94. Garraway IP, Sun W, Tran CP, Perner S, Zhang B, Goldstein AS, Hahm SA, Haider M, Head CS, Reiter RE, Rubin MA, Witte ON. Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate. 2010 Apr 01; 70(5):491-501. PMID: 19938015; PMCID: PMC2885946.
    95. Wallerand H, Bernhard JC, Culine S, Ballanger P, Robert G, Reiter RE, Ferrière JM, Ravaud A. Targeted therapies in non-muscle-invasive bladder cancer according to the signaling pathways. Urol Oncol. 2011 Jan-Feb; 29(1):4-11. PMID: 19914099.
      View in: PubMed
    96. Gore JL, Kwan L, Lee SP, Reiter RE, Litwin MS. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. 2009 Jun 16; 101(12):888-92. PMID: 19509365.
      View in: PubMed
    97. Li Y, Wang L, Zhang M, Melamed J, Liu X, Reiter R, Wei J, Peng Y, Zou X, Pellicer A, Garabedian MJ, Ferrari A, Lee P. LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res. 2009 Apr 15; 69(8):3332-8. PMID: 19351848.
      View in: PubMed
    98. Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, Reiter RE, Ferrière JM. The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol. 2010 Sep-Oct; 28(5):473-9. PMID: 19272800.
      View in: PubMed
    99. Reiter RE. The urologist role in basic and clinical translational research: Personal reflections of a urologic scientist. Urol Oncol. 2009 Mar-Apr; 27(2):127-8. PMID: 19285226.
      View in: PubMed
    100. Leyton JV, Olafsen T, Lepin EJ, Hahm S, Bauer KB, Reiter RE, Wu AM. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors. Clin Cancer Res. 2008 Nov 15; 14(22):7488-96. PMID: 19010866; PMCID: PMC2720761.
    101. Leyton JV, Olafsen T, Sherman MA, Bauer KB, Aghajanian P, Reiter RE, Wu AM. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng Des Sel. 2009 Mar; 22(3):209-16. PMID: 18957406.
      View in: PubMed
    102. Fondrevelle ME, Kantelip B, Reiter RE, Chopin DK, Thiery JP, Monnien F, Bittard H, Wallerand H. The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urol Oncol. 2009 May-Jun; 27(3):268-76. PMID: 18440840.
      View in: PubMed
    103. van de Poll-Franse LV, Kwan L, Reiter RE, Lee SP, Litwin MS. The influence of cardiovascular disease on health related quality of life in men with prostate cancer: a 4-year followup study. J Urol. 2008 Apr; 179(4):1362-7; discussion 1367. PMID: 18289562.
      View in: PubMed
    104. Hara T, Miyazaki H, Lee A, Tran CP, Reiter RE. Androgen receptor and invasion in prostate cancer. Cancer Res. 2008 Feb 15; 68(4):1128-35. PMID: 18281488.
      View in: PubMed
    105. Moore ML, Teitell MA, Kim Y, Watabe T, Reiter RE, Witte ON, Dubey P. Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate. 2008 Feb 01; 68(2):139-51. PMID: 18044730.
      View in: PubMed
    106. Reiter RE, Riggs S. What factors affect the PSA relapse-free survival times in patients treated with permanent seed brachytherapy? Nat Clin Pract Urol. 2007 Dec; 4(12):650-1. PMID: 17955047.
      View in: PubMed
    107. Pariente N, Morizono K, Virk MS, Petrigliano FA, Reiter RE, Lieberman JR, Chen IS. A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol Ther. 2007 Nov; 15(11):1973-81. PMID: 17653099.
      View in: PubMed
    108. Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 2007 Jun 01; 109(11):2239-47. PMID: 17455209.
      View in: PubMed
    109. Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother. 2007 May-Jun; 30(4):396-405. PMID: 17457214.
      View in: PubMed
    110. Lin K, Lee SP, Cho JS, Reiter RE, DeMarco JJ, Solberg TD. Improvements in prostate brachytherapy dosimetry due to seed stranding. Brachytherapy. 2007 Jan-Mar; 6(1):44-8. PMID: 17284385.
      View in: PubMed
    111. Rao DS, Gui D, Koski ME, Popoviciu LM, Wang H, Reiter RE, Said JW. An inverse relation between COX-2 and E-cadherin expression correlates with aggressive histologic features in prostate cancer. Appl Immunohistochem Mol Morphol. 2006 Dec; 14(4):375-83. PMID: 17122632.
      View in: PubMed
    112. Zemskova M, Wechter W, Bashkirova S, Chen CS, Reiter R, Lilly MB. Gene expression profiling in R-flurbiprofen-treated prostate cancer: R-Flurbiprofen regulates prostate stem cell antigen through activation of AKT kinase. Biochem Pharmacol. 2006 Nov 15; 72(10):1257-67. PMID: 16949054.
      View in: PubMed
    113. Lam JS, Reiter RE. Stem cells in prostate and prostate cancer development. Urol Oncol. 2006 Mar-Apr; 24(2):131-40. PMID: 16520277.
      View in: PubMed
    114. Reiter RE, Shurtleff B. What are the operating characteristics of PSA screening for prostate cancer? Nat Clin Pract Urol. 2006 Feb; 3(2):74-5. PMID: 16470202.
      View in: PubMed
    115. Gu Z, Yamashiro J, Kono E, Reiter RE. Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. Cancer Res. 2005 Oct 15; 65(20):9495-500. PMID: 16230414.
      View in: PubMed
    116. Wente MN, Jain A, Kono E, Berberat PO, Giese T, Reber HA, Friess H, Büchler MW, Reiter RE, Hines OJ. Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas. 2005 Aug; 31(2):119-25. PMID: 16024997.
      View in: PubMed
    117. Lam JS, Yamashiro J, Shintaku IP, Vessella RL, Jenkins RB, Horvath S, Said JW, Reiter RE. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res. 2005 Apr 01; 11(7):2591-6. PMID: 15814638.
      View in: PubMed
    118. Gu Z, Rubin MA, Yang Y, Deprimo SE, Zhao H, Horvath S, Brooks JD, Loda M, Reiter RE. Reg IV: a promising marker of hormone refractory metastatic prostate cancer. Clin Cancer Res. 2005 Mar 15; 11(6):2237-43. PMID: 15788672.
      View in: PubMed
    119. Thomas GV, Horvath S, Smith BL, Crosby K, Lebel LA, Schrage M, Said J, De Kernion J, Reiter RE, Sawyers CL. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res. 2004 Dec 15; 10(24):8351-6. PMID: 15623612.
      View in: PubMed
    120. Chin JL, Reiter RE. Molecular markers and prostate cancer prognosis. Clin Prostate Cancer. 2004 Dec; 3(3):157-64. PMID: 15636682.
      View in: PubMed
    121. Garraway IP, Seligson D, Said J, Horvath S, Reiter RE. Trefoil factor 3 is overexpressed in human prostate cancer. Prostate. 2004 Nov 01; 61(3):209-14. PMID: 15368472.
      View in: PubMed
    122. Chin JL, Reiter RE. Genetic alterations in prostate cancer. Curr Urol Rep. 2004 Jun; 5(3):157-65. PMID: 15161563.
      View in: PubMed
    123. Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said JW, Reiter RE. Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol. 2004 Mar; 171(3):1117-21. PMID: 14767283.
      View in: PubMed
    124. Freedland SJ, de Gregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Elashoff DA, Reiter RE, Aronson WJ. Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression. Urology. 2003 Jun; 61(6):1187-92. PMID: 12809895.
      View in: PubMed
    125. Cheng L, Reiter RE, Jin Y, Sharon H, Wieder J, Lane TF, Rao J. Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens. J Urol. 2003 Jun; 169(6):2094-100. PMID: 12771726.
      View in: PubMed
    126. Freedland SJ, deGregorio F, Sacoolidge JC, Elshimali YI, Csathy GS, Dorey F, Reiter RE, Aronson WJ. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol. 2003 Apr; 169(4):1325-30. PMID: 12629353.
      View in: PubMed
    127. Christiansen JJ, Rajasekaran SA, Moy P, Butch A, Goodglick L, Gu Z, Reiter RE, Bander NH, Rajasekaran AK. Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line. Prostate. 2003 Apr 01; 55(1):9-19. PMID: 12640656.
      View in: PubMed
    128. Palapattu GS, Reiter RE. Monoclonal antibody therapy for genitourinary oncology: promise for the future. J Urol. 2002 Dec; 168(6):2615-23. PMID: 12441996.
      View in: PubMed
    129. Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res. 2002 Dec; 1(2):113-21. PMID: 12496358.
      View in: PubMed
    130. Jain A, Lam A, Vivanco I, Carey MF, Reiter RE. Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol Endocrinol. 2002 Oct; 16(10):2323-37. PMID: 12351697.
      View in: PubMed
    131. Jalkut MW, Reiter RE. Role of prostate stem cell antigen in prostate cancer research. Curr Opin Urol. 2002 Sep; 12(5):401-6. PMID: 12172427.
      View in: PubMed
    132. DePrimo SE, Diehn M, Nelson JB, Reiter RE, Matese J, Fero M, Tibshirani R, Brown PO, Brooks JD. Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol. 2002 Jun 14; 3(7):RESEARCH0032. PMID: 12184806; PMCID: PMC126237.
    133. Watabe T, Lin M, Ide H, Donjacour AA, Cunha GR, Witte ON, Reiter RE. Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. Proc Natl Acad Sci U S A. 2002 Jan 08; 99(1):401-6. PMID: 11752398; PMCID: PMC117572.